Rational Design of RNA Demethylase FTO Inhibitors with Enhanced Antileukemia Drug-Like Properties
Journal of Medicinal Chemistry · 27.07.2023 · 66 (14) · 9731-9752
DOI: 10.1021/acs.jmedchem.3c00543 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 07.07.2023. Verfasst von Pan Xiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, C…. Hauptthemen laut MEDLINE: RNA, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Youth Innovation Promotion Association of the Chinese Academy of Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
The fat mass and obesity-associated protein (FTO) is an RNA N6-methyladenosine (m6A) demethylase highly expressed in diverse cancers including acute myeloid leukemia (AML). To improve antileukemia drug-like properties, we have designed 44/ZLD115, a flexible alkaline side-chain-substituted benzoic acid FTO inhibitor derived from FB23. A combination of structure-activity relationship analysis and lipophilic efficiency-guided optimization demonstrates that 44/ZLD115 exhibits better drug-likeness than the previously reported FTO inhibitors, FB23 and 13a/Dac85. Then, 44/ZLD115 shows significant antiproliferative activity in leukemic NB4 and MOLM13 cell lines. Moreover, 44/ZLD115 treatment noticeably increases m6A abundance on the AML cell RNA, upregulates RARA gene expression, and downregulates MYC gene expression in MOLM13 cells, which are consistent with FTO gene knockdown. Lastly, 44/ZLD115 exhibits antileukemic activity in xenograft mice without substantial side effects. This FTO inhibitor demonstrates promising properties that can be further developed for antileukemia applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- Analytical Research Center for Organic and Biological Molecules, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- School of Life Sciences, Fudan University, Shanghai 200433, China.
ORCID-Profile: Jianhua Gan, Ze Dong, Cai-Guang Yang
Förderung
- National Key Research and Development Program of China
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- National Natural Science Foundation of China
Zitieren
APA
Xiao, P., Duan, Z., Liu, Z., Chen, L., Zhang, D., Liu, L., Zhou, C., Gan, J., Dong, Z., & Yang, C. G. (2023). Rational Design of RNA Demethylase FTO Inhibitors with Enhanced Antileukemia Drug-Like Properties. Journal of Medicinal Chemistry, 66(14), 9731-9752. https://doi.org/10.1021/acs.jmedchem.3c00543
Vancouver
Xiao P, Duan Z, Liu Z, Chen L, Zhang D, Liu L, et al. Rational Design of RNA Demethylase FTO Inhibitors with Enhanced Antileukemia Drug-Like Properties. Journal of Medicinal Chemistry. 2023;66(14):9731-9752. doi:10.1021/acs.jmedchem.3c00543
BibTeX
@article{Xiao2023,
author = {Xiao, Pan and Duan, Zongliang and Liu, Zeyu and Chen, Liang and Zhang, Deyan and Liu, Lu and Zhou, Chen and Gan, Jianhua and Dong, Ze and Yang, Cai-Guang},
title = {Rational Design of RNA Demethylase FTO Inhibitors with Enhanced Antileukemia Drug-Like Properties},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {14},
pages = {9731--9752},
doi = {10.1021/acs.jmedchem.3c00543}
}
EUVIMED